Document is current

Article History

Received: 3 January 2022

Accepted: 2 August 2022

First Online: 12 August 2022

Declarations

:

: The SALT study was submitted to the local Research Ethics Commission of the University of Cologne (No. 17–078) for advice; the ethics committee (local Research Ethics Commission of the University of Cologne) waived the need for advice and for informed consent to participate due to the retrospective nature and the anonymous data capture strategy of this study []. The decision was made independently from the investigator or sponsor. The statement of the local Ethics Commission was submitted to all other Ethics Commissions in the respective participating centres.The study was registered at clinicaltrials.gov under NCT03353532.

: Not Applicable.

: OAC is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy – CECAD, EXC 2030 – 390661388 and has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, Merck/MSD, Pfizer, Scynexis, is a consultant to Actelion, Allecra Therapeutics, Al-Jazeera Pharmaceuticals, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini Ricerche,, Merck/MSD, Mylan Pharmaceuticals, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Roche Diagnostics Scynexis, Seres Therapeutics, Tetraphase, Vical, and received lecture honoraria from Astellas, Basilea, Gilead, Grupo Biotoscana, Merck/MSD and Pfizer.. BJL reports grants from Pfizer during the conduct of the study. SCM was a consultant to Octapharma. She has been receiving research grants from the University Hospital of Cologne (KoelnFortune), from the German center for infection research (DZIF; Clinical Leave Stipend), and from the German Mycological Society (Dr. Manfred Plepmpel Stipend). JS Stemler reports travel grants from German Society for Infectious Diseases (DGI) and from Meta-Alexander Foundation, and grants from Basilea Pharmaceutica International Ltd outside the submitted work. The remaining authors have nothing to declare.